Plasma transfusion (with natural levels of PEDF) into PEDF −/− type VI osteogenesis imperfecta individuals was conducted, but effects were not seen due to the low levels of PEDF administered, the low duration of dosing, and the low numbers of patients evaluated [146]. The gene discussed is SERPINF1; the disease is osteogenesis imperfecta.